Intravenous (IV) Ketamine in Treatment-Resistant Bipolar Depression (TRBD)

ID Number 08-1422

Principal Investigator(s)
James Murrough

Department(s) or Division(s)

Research Entity
Mood and Anxiety Disorders Program - MAP


Current treatments for bipolar depression are few and often inadequate. Recently, a single intravenous (IV) dose of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine has demonstrated rapid antidepressant effects in severe unipolar depression. Therefore, the objective of the current study is to investigate the safety and efficacy of a single IV dose of ketamine in treatment-resistant bipolar depression (TRBD).

Contact Information
Chris Bailey
(212) 241-6383

Recruiting Patients: No